Hospital
Bridgton Hospital
Bridgton Hospital was paid $2.52M by Medicaid between Jan 2018 and Dec 2024, across 261 billing codes. Its largest line is 99285, emergency room visit (most serious) — 13% of everything it billed.
33Billing provider infoBRIDGTON HOSPITAL
BRIDGTON, ME 04009
BRIDGTON, ME 04009
33aNPI1154370153assigned 05/08/2006
33bProvider typeCritical Access Hospital
28Total paid$2.52M
24GClaims511,560
24DCodes billed261
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Maine
Rank by total paid#6 of 14
Median peer was paid$1.76M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,578 | $353K | |
| 2019 | 76,535 | $370K | |
| 2020 | 70,326 | $301K | |
| 2021 | 75,346 | $368K | |
| 2022 | 74,974 | $332K | |
| 2023 | 74,602 | $379K | |
| 2024incomplete | 65,199 | $417K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 8,423 | 5,636 | $330K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 18,863 | 12,487 | $291K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.1% | 17,806 | 11,959 | $179K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 2,386 | 2,232 | $172K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.6% | 34,755 | 26,545 | $167K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.9% | 10,214 | 8,327 | $124K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.5% | 1,812 | 1,672 | $114K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.0% | 43,468 | 32,132 | $102K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.5% | 2,907 | 2,285 | $89K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.9% | 4,195 | 3,461 | $73K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 4,469 | 3,956 | $60K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 12,653 | 4,258 | $56K |
249 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 6,370 | $52K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 3,054 | $51K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 3,892 | $42K |
| 80053 | Comprehensive metabolic panel | 1.6% | 19,447 | $40K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.3% | 26,760 | $34K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 6,342 | $29K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 4,243 | $28K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 474 | $28K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.1% | 290 | $27K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.0% | 291 | $26K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.0% | 2,950 | $25K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,914 | $24K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 881 | $20K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 405 | $19K |
| 96376 | <1% | 869 | $13K | |
| 97161 | <1% | 1,250 | $11K | |
| 71250 | <1% | 129 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,645 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,710 | $10K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 12,082 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,611 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,958 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,020 | $9K |
| 73630 | <1% | 708 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 824 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,761 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 757 | $8K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,838 | $8K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 381 | $7K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,552 | $7K |
| 90715 | <1% | 1,464 | $7K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 4,014 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,982 | $6K |
| 80299 | <1% | 4,175 | $6K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 573 | $5K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,109 | $5K |
| 83880 | <1% | 1,438 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 965 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 66 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 726 | $4K |
| 73030 | <1% | 236 | $4K | |
| 73562 | <1% | 173 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 65 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,352 | $3K |
| 84484 | <1% | 3,207 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,257 | $3K |
| 82728 | <1% | 1,968 | $3K | |
| 87088 | <1% | 3,640 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,058 | $3K |
| 82607 | <1% | 1,715 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 136 | $3K |
| 73610 | <1% | 368 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 45 | $3K |
| 98927 | <1% | 472 | $3K | |
| 96367 | <1% | 203 | $2K | |
| 85027 | <1% | 3,981 | $2K | |
| 90837 | Psychotherapy session, about an hour | <1% | 996 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,394 | $2K |
| 80069 | <1% | 464 | $2K | |
| 83735 | <1% | 3,576 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,923 | $2K |
| 99443 | <1% | 530 | $2K | |
| 72100 | <1% | 84 | $2K | |
| 84439 | <1% | 1,477 | $2K | |
| 85610 | <1% | 4,884 | $2K | |
| 86803 | <1% | 974 | $2K | |
| 80061 | Lipid panel | <1% | 6,624 | $2K |
| 83550 | <1% | 1,202 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 256 | $2K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,633 | $1K |
| 81001 | <1% | 4,117 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,824 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 157 | $1K |
| 96127 | <1% | 1,731 | $1K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 735 | $1K |
| 87186 | <1% | 1,631 | $1K | |
| 87040 | <1% | 1,280 | $1K | |
| 83540 | <1% | 1,292 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 26 | $1K |
| 83605 | <1% | 2,201 | $1K | |
| 84460 | <1% | 987 | $1K | |
| 80051 | <1% | 1,973 | $1K | |
| 83690 | <1% | 3,448 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,246 | $1K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,792 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,583 | $1K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,594 | $929.08 |
| 99442 | <1% | 418 | $927.41 | |
| 86140 | <1% | 1,688 | $877.37 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,599 | $868.28 |
| 82043 | <1% | 510 | $811.37 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 125 | $773.44 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 313 | $741.81 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 174 | $727.69 |
| 73502 | <1% | 58 | $701.92 | |
| 97165 | <1% | 93 | $698.07 | |
| 93971 | <1% | 24 | $638.85 | |
| 82565 | <1% | 2,167 | $630.43 | |
| 85651 | <1% | 1,500 | $581.09 | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 7,568 | $579.21 |
| 84520 | <1% | 2,122 | $572.85 | |
| 81003 | <1% | 2,277 | $568.43 | |
| G0008 | Administration of influenza virus vaccine | <1% | 832 | $554.95 |
| 73110 | <1% | 54 | $542.47 | |
| 84450 | <1% | 732 | $540.50 | |
| 76830 | Ultrasound, transvaginal | <1% | 83 | $514.39 |
| 81002 | <1% | 1,273 | $439.02 | |
| 98926 | <1% | 379 | $429.46 | |
| 99205 | Prolong outpt/office vis | <1% | 94 | $429.14 |
| 90677 | <1% | 58 | $406.57 | |
| 73130 | <1% | 57 | $374.30 | |
| 97116 | <1% | 459 | $367.23 | |
| 82746 | <1% | 390 | $366.65 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,004 | $359.82 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 285 | $358.68 |
| 87077 | <1% | 782 | $355.38 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 520 | $348.34 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 380 | $337.32 |
| 93975 | <1% | 27 | $327.36 | |
| 86352 | <1% | 255 | $313.20 | |
| 90662 | <1% | 255 | $312.06 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,925 | $304.82 |
| 11721 | <1% | 30 | $304.34 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 315 | $292.19 |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 105 | $292.12 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 189 | $287.76 |
| 87070 | <1% | 986 | $273.80 | |
| 90686 | <1% | 3,574 | $273.34 | |
| 76536 | <1% | 14 | $268.98 | |
| 82805 | <1% | 234 | $262.47 | |
| 85018 | <1% | 532 | $253.18 | |
| J3490 | Unclassified drugs | <1% | 287 | $235.96 |
| 81025 | <1% | 2,573 | $222.87 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,544 | $200.72 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,075 | $193.46 |
| 94760 | <1% | 179 | $185.36 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 508 | $183.06 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 47 | $177.79 |
| 36416 | <1% | 336 | $168.19 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 274 | $164.83 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 82 | $155.71 |
| 94060 | <1% | 26 | $148.68 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 44 | $148.64 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,225 | $147.40 |
| 71271 | <1% | 87 | $146.90 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 152 | $146.37 |
| 85380 | <1% | 330 | $137.36 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 253 | $132.13 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 129 | $131.06 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,225 | $130.45 |
| 82947 | <1% | 1,442 | $122.39 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,054 | $112.26 |
| 87205 | <1% | 349 | $110.16 | |
| 92526 | <1% | 249 | $109.20 | |
| 84153 | <1% | 13 | $103.48 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 861 | $98.86 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 17 | $95.98 |
| 87480 | <1% | 135 | $91.06 | |
| 87510 | <1% | 135 | $91.06 | |
| 87660 | <1% | 135 | $91.06 | |
| 90673 | <1% | 26 | $86.64 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 152 | $86.49 |
| 87581 | <1% | 313 | $80.64 | |
| 86618 | <1% | 151 | $78.17 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 244 | $73.30 |
| 87081 | <1% | 805 | $72.23 | |
| 82570 | <1% | 69 | $69.35 | |
| 85730 | <1% | 133 | $69.33 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 15 | $58.51 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 134 | $57.70 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 319 | $51.52 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 193 | $47.15 |
| Q3014 | Telehealth originating site facility fee | <1% | 2,864 | $46.09 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 96 | $40.78 |
| 82248 | <1% | 120 | $35.65 | |
| 88142 | <1% | 422 | $27.28 | |
| 87147 | <1% | 557 | $26.02 | |
| 86703 | <1% | 80 | $24.16 | |
| 82550 | <1% | 54 | $21.21 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 217 | $20.45 |
| 90656 | <1% | 273 | $19.01 | |
| 99441 | <1% | 12 | $15.32 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 46 | $14.67 |
| 85014 | <1% | 13 | $13.24 | |
| 84100 | <1% | 47 | $12.82 | |
| 83655 | <1% | 140 | $10.40 | |
| 84481 | <1% | 74 | $10.33 | |
| 86038 | <1% | 61 | $9.89 | |
| 99406 | <1% | 623 | $5.81 | |
| 84075 | <1% | 45 | $5.78 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 3,522 | $5.64 |
| 82247 | <1% | 55 | $5.40 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 262 | $3.96 |
| 87207 | <1% | 14 | $3.80 | |
| 82040 | <1% | 44 | $3.23 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 48 | $2.20 |
| 81000 | <1% | 84 | $1.49 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 24 | $0.88 |
| 97162 | <1% | 29 | $0.75 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 395 | $0.03 |
| 90744 | 0% | 111 | $0.00 | |
| 91301 | 0% | 606 | $0.00 | |
| 86850 | 0% | 55 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 550 | $0.00 |
| 90716 | 0% | 24 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 157 | $0.00 |
| 90619 | 0% | 37 | $0.00 | |
| 90698 | 0% | 146 | $0.00 | |
| 90651 | 0% | 105 | $0.00 | |
| D1206 | Topical application of fluoride varnish | 0% | 124 | $0.00 |
| 0012A | 0% | 303 | $0.00 | |
| 0011A | 0% | 296 | $0.00 | |
| 90732 | 0% | 29 | $0.00 | |
| 0064A | 0% | 82 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 95 | $0.00 |
| 87807 | 0% | 54 | $0.00 | |
| 87340 | 0% | 14 | $0.00 | |
| 91306 | 0% | 28 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 12 | $0.00 |
| 86901 | 0% | 58 | $0.00 | |
| 99174 | 0% | 13 | $0.00 | |
| 90680 | 0% | 12 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 3,062 | $0.00 |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 0% | 3,596 | $0.00 |
| 90461 | 0% | 1,397 | $0.00 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 1,968 | $0.00 |
| 92552 | 0% | 856 | $0.00 | |
| 90681 | 0% | 118 | $0.00 | |
| 90473 | 0% | 42 | $0.00 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 0% | 3,535 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 225 | $0.00 |
| 0002A | 0% | 13 | $0.00 | |
| 99177 | 0% | 550 | $0.00 | |
| 90734 | 0% | 293 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 81 | $0.00 |
| 90670 | 0% | 743 | $0.00 | |
| 90685 | 0% | 195 | $0.00 | |
| 99173 | 0% | 39 | $0.00 | |
| 90700 | 0% | 50 | $0.00 | |
| 90633 | 0% | 283 | $0.00 | |
| 91300 | 0% | 35 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 31 | $0.00 |
| 86900 | 0% | 58 | $0.00 | |
| 90649 | 0% | 25 | $0.00 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 0% | 12 | $0.00 |
| 87634 | 0% | 19 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 15 | $0.00 |
| 82272 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORIN, SUE (REGIONAL MANAGER PHYSICIAN PRACTICE)
| Provider | Location | Paid |
|---|---|---|
| Rumford Hospital | Rumford, ME | $2.35M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.